Dec. 09, 2025
The global pet pharmaceutical market is experiencing robust growth, driven by rising pet humanization, increasing preventive healthcare awareness, and expanding demand for high-quality pet health solutions. According to the latest industry data, the market is projected to reach $45 billion by 2025, with three core segments—deworming, joint care, and urinary health—leading the charge with a year-on-year growth rate exceeding 30%. For Chinese pet health brands, this trend unlocks unprecedented opportunities to expand their global footprint.
Core Segments Driving Market Growth
Deworming products remain the largest contributor, fueled by tropical and subtropical regions’ high parasite prevalence and growing adoption of “internal-external combined deworming” concepts. Products with broad-spectrum efficacy and long-acting protection (e.g., 12-week coverage) are in high demand, as pet owners seek convenient, science-backed solutions.
Joint care has emerged as a fast-growing segment, driven by aging pet populations and increased focus on mobility. Nutritional supplements with glucosamine, chondroitin, and Omega-3 fatty acids are popular among owners of large breeds and senior pets, with a notable preference for palatable chewable formats.
Urinary health products are gaining traction amid rising cases of urinary stones and infections, especially in high-temperature regions. Formulas that promote hydration and maintain urinary tract balance are seeing strong sales, as preventive care becomes a priority for pet parents.
Chinese Brands’ Competitive Advantages & Global Opportunities
Chinese pet pharmaceutical brands, such as WERVIC under Weierli Group, are leveraging key strengths to penetrate international markets. With 24+ years of R&D and production experience, these brands benefit from mature supply chains, cost-effectiveness, and compliance with global standards (e.g., RU GMP certification). Their ability to customize formulas, packaging, and dosage forms also caters to diverse regional needs—from Southeast Asia’s demand for waterproof dewormers to Europe’s preference for natural ingredients.
The rise of e-commerce and cross-border trade platforms has further lowered entry barriers. Chinese brands can now directly reach B2B partners (veterinary clinics, distributors) and end consumers in 50+ countries, bypassing traditional distribution bottlenecks. Additionally, growing recognition of “Made in China” quality in animal health has enhanced trust, positioning Chinese brands as reliable alternatives to established Western players.
Future Outlook: Prioritize Innovation & Localization
To seize these opportunities, Chinese brands must focus on innovation—investing in R&D for targeted solutions (e.g., breed-specific joint care, low-stress deworming products) and digital marketing to build global brand awareness. Localization is equally critical: adapting to regional regulations, cultural preferences, and distribution channels will ensure long-term success.
As the global pet pharmaceutical market evolves, Chinese brands are well-positioned to become key players. With a focus on quality, innovation, and customer-centricity, they can tap into the $45 billion market, bringing trusted pet health solutions to families worldwide.
Visit WERVIC’s official site to explore our global-ready product portfolio: https://www.victorypharmgroup.com/
